^
Association details:
| Biomarker: | CLDN18.2 overexpression |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | osemitamab (TST001) (CLDN18.2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase I study of TST001, a high affinity humanized anti-CLDN18.2 monoclonal antibody, in combination with capecitabine and oxaliplatin (CAPOX) as a first-line treatment of advanced G/GEJ cancer.
Published date:
05/26/2022
Excerpt:
12 subjects were dosed with TST001 with a dose range from 1 to 8mg/kg Q3W in combination with the standard dose of CAPOX in the dose escalation phase and one subject with central lab tested Claudin 18.2 overexpression was dosed in the expansion phase of TST001 at 6mg/kg Q3W with CAPOX. TST001 in combination with CAPOX in first line gastric cancer patients is safe and encouraging anti-tumor activities have been observed.
Secondary therapy:
CAPOX
DOI:
10.1200/JCO.2022.40.16_suppl.4062
Trial ID:
